(Q30469617)

21 June 2017

1 reference

title

Erosion of psoriatic plaques: an early sign of methotrexate toxicity (English)

1 reference

21 June 2017

1 reference

Pearce HP

1

1 reference

PubMed ID

8912599

21 June 2017

Wilson BB

series ordinal

2

1 reference

PubMed ID

8912599

21 June 2017

language of work or name

English

0 references

publication date

1 November 1996

1 reference

Journal of the American Academy of Dermatology

21 June 2017

1 reference

21 June 2017

35

1 reference

21 June 2017

5 Pt 2

1 reference

21 June 2017

835-838

1 reference

Therapeutic suppression of tissue reactivity. I. Comparison of the effects of cortisone and aminopterin

21 June 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Effect of aminopterin on epithelial tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Aminopterin for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Treatment of psoriasis with folic acid antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Morphologic and physiologic effects of chemotherapeutic agents in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Further observations on aminopterin for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Methotrexate vs. aminopterin for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

The use of methotrexate in the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

THE TREATMENT OF PSORIASIS WITH AMINOPTERIN

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

A study of the folic acid antagonists in the treatment of psoriasis (aminopterin vs. methotrexate vs. aminopterin and a corticosteroid)

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

METHOTREXATE IN THE TREATMENT OF PSORIASIS: A CONTROLLED CLINICAL TRIAL

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

The Use of Folic Acid Antagonists and Steroids in Treatment of Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

THE TREATMENT OF PSORIASIS WITH FOLIC ACID ANTAGONISTS

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

AMINOPTERIN FOR PSORIASIS. A DECADE'S OBSERVATION.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

PARENTERAL VS. ORAL FOLIC ACID ANTAGONISTS

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Methotrexate for Psoriasis: A Preliminary Report

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Management of psoriasis using methotrexate orally in a single weekly dose

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Methotrexate for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Systemic corticosteroids and folic acid antagonists in the treatment of generalized pustular psoriasis. Evaluation and prognosis based on the study of 104 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Intermittent high dose oral methotrexate therapy in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Drug interaction in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Methotrexate-induced necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Two patterns of skin ulceration induced by methotrexate in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Methotrexate toxicity precipitated by azapropazone

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Near fatal drug interactions with methotrexate given for psoriasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Erosion of psoriatic plaques after chronic methotrexate administration

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Pancytopenia following low-dose oral methotrexate therapy for psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Methotrexate and nonsteroidal antiinflammatory drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Methotrexate: clinical pharmacology, current status and therapeutic guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Methotrexate guidelines--revised

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

Methotrexate side-effects

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990097-3

7 January 2021

10.1016/S0190-9622(96)90097-3

Identifiers

DOI

1 reference

21 June 2017

1 reference

PubMed ID

8912599